The trial achieved both of those its Principal endpoints, with semaglutide 2.4 mg demonstrating statistically substantial and excellent improvements in liver fibrosis without having worsening of steatohepatitis, in addition to resolution of steatohepatitis without having worsening of liver fibrosis in those with MASH in comparison to placebo.oneYou